Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00081939 · ClinicalTrials.gov registry record · Phase 2
UARK 2003-33, Total Therapy III
A Phase 2 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 303
- Enrollment target
NCT00081939 is a Phase 2 study that has completed, run by University of Arkansas. The registered enrollment target is 303 participants.
The verdict
NCT00081939, a Phase 2 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 303 participants
- Enrollment target
Study Summary
There have been two previous Total Therapy studies for multiple myeloma (MM) at the Myeloma Institute for Research and Therapy (MIRT): Total Therapy I (from 1989 through 1994) and Total Therapy II (from 1996 to 2004). Results have shown that patients treated on these studies had better outcomes (meaning patients have lived longer and had better responses to treatment) when compared to patients treated with standard chemotherapy. With this new study, Total Therapy III, researchers will take what they have learned from the first two studies and add new treatment strategies to try to improve the outcomes even more, especially for patients with chromosome abnormalities.
Interventions
- DRUG Thalidomide
- DRUG Velcade
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 303 participants |
| Start Date | 2004-01 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00081939
The ClinicalTrials.gov registry entry for NCT00081939 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 303 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Thalidomide is the first listed.
NCT00081939 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00081939 about?
NCT00081939 is a clinical study titled "UARK 2003-33, Total Therapy III". There have been two previous Total Therapy studies for multiple myeloma (MM) at the Myeloma Institute for Research and Therapy (MIRT): Total Therapy I (from 1989 through 1994) and Total Therapy II (from 1996 to 2004). Results have shown that patients treated on these studies had better outcomes (mea...
What is the current status of trial NCT00081939?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 303 participants. The study started on 2004-01. Estimated completion is 2014-09.
What interventions are being tested in trial NCT00081939?
The interventions under investigation include: Thalidomide (DRUG), Velcade (DRUG).
Who is sponsoring clinical trial NCT00081939?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.